PRC-063 100 mg

DRUG2 trials

Sponsors

Rhodes Pharmaceuticals, L.P.

Conditions

ADHDAttention Deficit Hyperactivity Disorder (ADHD)

Phase 3

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

CompletedNCT02139124

Rhodes Pharmaceuticals, L.P.ADHD

Start: 2014-04-30End: 2015-01-31Updated: 2019-05-07

PRC-063 in an ADULT Workplace Environment

CompletedNCT02225639

Rhodes Pharmaceuticals, L.P.Attention Deficit Hyperactivity Disorder (ADHD)

Start: 2014-08-31End: 2015-05-31Updated: 2015-07-09

Related Papers

An Exploratory Study of Functional Outcome in Stimulant Treatment of ADHD in Adults

Journal of Attention Disorders2026-05-05

A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajustée par appariement (MAIC) entre centanafadine et le chlorhydrate de méthylphénidate chez les adultes atteints d’un trouble déficitaire de l'attention avec ou sans hyperactivité (TDAH) : Résultats en matière d’innocuité et d’efficacité à court terme

The Canadian Journal of Psychiatry2025-06-021 citations

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHD

Journal of Attention Disorders2021-06-308 citations

Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.

2021-05-316 citations